Answers are grounded in this paper and cite their sources.
Nanostructured lipid carriers (NLCs) are lipid-based nanoparticles created from a blend of solid and liquid lipids, with surfactants that help stabilize the mixture. The introduction of liquid lipid can disrupt the orderly arrangement of solid lipid, resulting in spaces that can hold a drug. This structure may enhance drug loading or minimize drug loss during storage, particularly in comparison to certain solid lipid nanoparticle (SLN) systems. The benefits of this approach depend on factors such as the type of drug, the lipid mixture, the surfactant system, and the methods used in manufacturing. This review explores the foundational aspects of NLC formulation, the selection of materials, preparation techniques, and the analytical assessments used to characterize these systems. It also looks at their reported applications across various administration routes, including oral, dermal, transdermal, ocular, pulmonary, nasal, and brain-targeted delivery. The review places significant emphasis on the challenges of transforming a laboratory formulation into a reliable pharmaceutical product, such as variability between batches, inadequate understanding of particle structure, issues with physical and chemical stability, sterilization, scaling up, route-specific safety, and regulatory requirements. Potential solutions to these challenges include Quality-by-Design (QbD), Design of Experiments (DoE), advanced analytical techniques, continuous processing, lyophilization, and surface modification. It is important to note that NLCs should not be seen as universally superior carriers; their effectiveness must be established for each drug and intended delivery route, ideally in comparison to an appropriate reference and using clinically significant outcomes.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: